Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat with RVD in Newly Diagnosed Multiple Myeloma
NCT02720510Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in multiple myeloma (MM), sponsored by Novartis. Started Jun 2016; status: terminated.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02720510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720510.